Glad we didn't start a P3.
Plenty of tiny biopharma companies like IPIX try to take their drug through P3 to NDA on their own only to find disaster.
Money runs out, CRL sets things back, unforeseen trial delays or glitches derail timelines and protocols, CRO's don't hold up to their end of it.
It's extremely difficult for a tiny biopharma to cross the finish line of a P3 successfully and to a FDA approval.
Dilution, reverse splits, etc.
Saying the share price would have stayed $2-$3 for IPIX during P3 in order to raise funds for the company and trial, and fund other trials is pure speculation with plenty of examples to the contrary.
The take down was so severe, a P3 trial would not have warded off the negative effects.
I think the "value building strategy" was/is the right way to go, and advancing Purisol to this point for a deal was the best way to go.
What tiny biopharma company doesn't have things to complain about.
IPIX has 3 potential blockbuster platforms - multiple billion dollar indications from each platform.
I am not expecting news from P's p2b to be the game changer because trial news hasn't changed the share price as expected.
Perhaps P's p2b will change the sp in an upward direction/momentum to up-listing where legit analysts will cover and institutions will invest.
But the game-changing/life altering events happen with big fish partners and licenses.
I expect a deal/license will affect the share price in a permanent upward direction.
If IPIX delivers on its vision, this will be a stock for the ages.
